Arcellx Inc

Latest Results (21.11.2025):

Arcellx, Inc. reported third quarter 2025 results (Q3 2025): cash, cash equivalents and marketable securities of about $576.0 million with an expected runway into 2028; collaboration revenue of $4.9 million (down sharply year‑over‑year); R&D spending slightly lower while G&A rose materially; and a net loss of $55.8 million (‑$0.99 per share).

Cash position and runway

Cash, cash equivalents and marketable securities totaled $575.974 million as of September 30, 2025 (reported as ~$576.0M). Management expects these resources to fund operations into 2028. Cash declined from $625.652 million at December 31, 2024.

Revenue

Collaboration revenue was $4.949 million in Q3 2025 versus $26.030 million in Q3 2024, a decrease of $21.1 million, primarily due to completion of dosing and manufacturing of anito‑cel in the iMMagine‑1 trial in Q4 2024.

Research & development

R&D expense was $35.088 million in the quarter, down from $39.173 million a year earlier (a $4.1M decrease), largely reflecting the same completion of anito‑cel dosing and manufacturing activity.

General & administrative

G&A expense rose to $31.637 million in Q3 2025 from $20.473 million in Q3 2024 (an $11.1M increase), driven by higher commercial readiness costs and personnel expenses, including non‑cash stock‑based compensation.

Profitability

Net loss for Q3 2025 was $55.781 million versus a $25.867 million loss in Q3 2024. Loss from operations was $61.776 million, partially offset by other income of $5.995 million. Net loss per share was $0.99 (basic and diluted).

Balance sheet and shares

Selected totals as of September 30, 2025: total assets $655.918 million, total liabilities $215.141 million, and total stockholders' equity $440.777 million. Weighted‑average common shares outstanding (basic and diluted) for the quarter were 56,587,167.